BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole
Nutrigenomics is the study of how genes and diet (nutrients) interact. Gene variants (genetic differences) predict how an individual’s body will respond to certain nutrients.
Philips FetView will offer real-time, off cart remote patient management with access to data from any ultrasound system
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.
He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division
If implemented across the world, it has the capability to save over 100,000 lives annually
Subscribe To Our Newsletter & Stay Updated